Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposome + Fruquintinib + Sintilimab in Advanced Gastric Cancer
NCT07819019Phase 2Not yet recruiting
- Sponsor
- Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2026
- Primary completion
- Oct 2028
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome injection, fruquintinib and sintilimab in gastric cancer (GC), sponsored by Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-Free Survival at 12 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
irinotecan liposome injectionfruquintinibsintilimab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT07819019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07819019.